These highly validated antibodies from Atlas Antibodies target several key diagnostic, and exploratory targets relevant for glioma classification, including ATRX, IDH1, and GFAP. These antibodies and targets have been identified using data from the Human Protein Atlas glioma transcriptome project, prognostic data and clinical reviews on the tumour microenvironment.
Receive a 20% discount off any PrecisA monoclonal antibodies
Benefits of using these antibodies:
• From the Triple A Polyclonal and PrecisA Monoclonal ranges
• Highly validated for IHC, western blot and/or ICC-IF
• Covered by the Cambridge Bioscience Success Guarantee
Validation images
Multiplexed IHC-IF staining of oligodendroglioma showing ATRX (nuclear, red) and GFAP (cytoplasmic, green) immunoreactivity in tumour cells using Anti-ATRX antibody (AMAb90784) and Anti-GFAP antibody (AMAb91033). Nuclei were counterstained with DAPI.
Multiplexed IHC-IF staining of glioblastoma multiforme (left) and oligodendroglioma (right) showing ATRX (red) and IDH1 (green) immunoreactivity in tumour cells using Anti-ATRX antibody (left: HPA001906, right: AMAb90784, clone 0537) and Anti-IDH1 antibody (AMAb90578, clone 0219). Nuclei were counterstained with DAPI
Below is a small selection of glioma research antibodies available. For a full list please contact our Atlas Antibodies Specialist.
